A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-831 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs TAK 831 (Primary)
- Indications Cerebellar ataxia; Schizophrenia
- Focus Adverse reactions
- Sponsors Takeda
- 13 Sep 2016 Status changed from suspended to recruiting.
- 16 Jun 2016 Planned End Date changed from 1 May 2016 to 1 Dec 2016.
- 16 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 Dec 2016.